SCHEMBL31679360

CCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CS)[C@@H](C)CC)C(=O)N[C@@H](CS)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 11)

	gene	UniProt	supporting neighbours	confidence
▸	OPRD1	P41143	8/20	0.55

▸	OPRM1	P35372	3/20	0.54

▸	NMUR2	Q9GZQ4	4/20	0.53

▸	NMUR1	Q9HB89	4/20	0.53

▸	NTSR1	P30989	3/20	0.52

▸	MAPK8	P45983	1/20	0.51

▸	MAPK9	P45984	1/20	0.51

▸	MAPK10	P53779	1/20	0.51

▸	NTSR2	O95665	1/20	0.50

▸	AGTR1	P30556	1/20	0.50

▸	AGTR2	P50052	1/20	0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL31679423	0.94	AGTR2 (0.51)	OPRD1NMUR2NMUR1NTSR1MAPK8
SCHEMBL31679418	0.94	OPRD1 (0.54)	OPRD1OPRM1NTSR1MAPK8MAPK9
SCHEMBL31679451	0.93	AGTR2 (0.52)	OPRD1NMUR2NMUR1NTSR1MAPK8
SCHEMBL31679462	0.93	AGTR2 (0.52)	OPRD1NMUR2NMUR1NTSR1MAPK8
SCHEMBL31679406	0.92	MAPK8 (0.51)	OPRD1NMUR2NMUR1NTSR1MAPK8
SCHEMBL31679381	0.91	AGTR2 (0.50)	OPRD1NMUR2NMUR1NTSR1MAPK8
SCHEMBL31679388	0.91	OPRD1 (0.50)	OPRD1OPRM1NMUR2NMUR1NTSR1
SCHEMBL31679481	0.91	OPRD1 (0.55)	OPRD1OPRM1NTSR1NTSR2AGTR1
SCHEMBL31679460	0.90	MAPK8 (0.56)	OPRD1OPRM1NMUR2NMUR1NTSR1
SCHEMBL31679341	0.90	AGTR2 (0.52)	OPRD1NTSR1NTSR2AGTR1AGTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
EP-4610269-A1	UROKINASE PLASMINOGEN ACTIVATOR SURFACE RECEPTOR (UPAR) LIGANDS FOR DIAGNOSTIC OR THERAPEUTIC USE	3B Pharmaceuticals GmbH (DE)	2025-09-03	—	—	EP	disclosed